Search

for
Search:

Research

5 / 1000+ results

research 42175 PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials

September 2023 in “Journal of the American Academy of Dermatology”

This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials.

research Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies

January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)”

In this study, the safety profile of the prodrug CAP7.1 was found to be similar to other topoisomerase inhibitors, with myelosuppression as the main dose-limiting toxicity.

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

2 citations , November 2025 in “Journal of the American Academy of Dermatology”

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

research Anti-acne drugs in phase 1 and 2 clinical trials

27 citations , June 2017 in “Expert opinion on investigational drugs”

This review discusses ongoing and past trials for novel acne treatments, focusing on topical agents with potential sebosuppressive, antimicrobial, or anti-inflammatory effects, without reporting new clinical results.

Multicentric Parallel Phase II Trial of the Polo-Like Kinase 1 Inhibitor BI 2536 in Patients With Advanced Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, and Melanoma. The First Protocol of the European Organization for Research and Treatment of Cancer Network of Core Institutes

research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

93 citations , May 2010 in “European Journal of Cancer”

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

View more "phase 1 trials" in research →

Community Join

5 / 1000+ results

community Verteporfin Phase 1 Human Clinical Trial In The Works - Research

92 upvotes 1 year ago

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

community HMI-115 Australian Phase 1 Trial completed?

20 upvotes 2 years ago

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

community Han Bio Aims for Phase 1 Clinical Trials in 2027 after successful hair growth in mice

in Research/Science 248 upvotes 1 year ago

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.

community KX826 New Phase 3 Trial In China for 2025: 1.0% concentration

62 upvotes 1 year ago

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment

46 upvotes 1 year ago

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

View more "phase 1 trials" in community →

Learn

7 / 33 results

learn Follistatin

glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin

Are there any clinical studies supporting follistatin as a hair loss treatment? There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.
How does follistatin compare to finasteride or dutasteride for treating androgenic alopecia? Finasteride and dutasteride are prescription drugs with large controlled trials showing they lower DHT and slow androgenic hair loss, at the cost of documented hormonal side effects; follistatin targets a different, regenerative pathway but has only one small phase 1 human trial behind it, so it is experimental with unknown safety rather than a comparable alternative.
What is follistatin, and how does it influence hair follicle growth and regeneration? Follistatin blocks activin and related growth-inhibiting proteins, which in laboratory and animal work is described as keeping hair follicles in their growth phase; the only verifiable human evidence is a single small 2011 phase 1 injection trial, so follistatin remains experimental and is not an approved hair-loss treatment.

learn Clascoterone

Is clascoterone suitable for both men and women? Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.

learn Epidermal Growth Factor

learn PP405

mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

learn Latanoprost

glaucoma medication with hair follicle stimulant effects

learn Hair Multiplication

extract, clone, and reinsert your own hair cells

learn Hair Transplant

Is shedding normal after a hair transplant? Shedding is normal after a hair transplant and usually resolves within weeks.

View more "phase 1 trials" in learn →

Clinics

1 / 13 results

Hair Systems
Mane PhaseRancho Cucamonga, CA · US

Experts

— no results

Try a deeper search in experts →